Achaogen Inc Cmn (AKAO) 3.86 $AKAO
Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting
GlobeNewswire - Thu Jun 09, 7:30AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced six upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2016 Annual Meeting. The Company and its collaborators will make two oral presentations and present four posters at the event, which will be held at the Boston Convention and Exhibition Center (BCEC) from June 16 to 20, 2016. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen (AKAO) Shows Strength: Stock Moves 13% Higher
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:15AM CDT
Achaogen, Inc. (AKAO) shares rose around 13% in the last trading session.
AKAO: 3.86 (-0.27), JNP: 6.91 (-0.06)
Achaogen Adds Tobin Schilke as Chief Financial Officer
GlobeNewswire - Fri Jun 03, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Mr. Tobin Schilke as Chief Financial Officer, effective July 5, 2016. Mr. Schilke will serve as Achaogen's principal financial and accounting officer and will report to Kenneth Hillan, Chief Executive Officer.
AKAO: 3.86 (-0.27)
Achaogen Raises $25 Million in Private Placement
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has entered into an agreement to sell shares of its common stock and warrants to purchase shares of its common stock for aggregate gross proceeds of approximately $25 million in a private placement. New Enterprise Associates (NEA), one of the largest biotechnology investors worldwide, led the placement and was joined by EcoR1 Capital, LLC and additional new investors. Achaogen expects to use proceeds of the financing to advance its research and development programs and for general corporate purposes. The Company's lead product candidate, plazomicin, is being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
SLRC: 18.78 (-0.07), AKAO: 3.86 (-0.27)
Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded $20 million for an additional option, Option 3, on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of plazomicin. Plazomicin is the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
GlobeNewswire - Thu Jun 02, 6:55AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has achieved over 50 percent patient enrollment in its ongoing Phase 3 EPIC registration clinical trial of plazomicin. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen and Crystal Bioscience Enter into Collaboration and License Agreement to Identify and Develop Antibodies for Multiple Targets
GlobeNewswire - Tue May 10, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, and Crystal Bioscience, Inc. (Crystal Bioscience), an antibody discovery company with a patented chicken-based discovery platform "powered by evolution," today announced that they have entered into a multiyear Collaboration and License Agreement to discover unique monoclonal antibodies against multiple targets. Achaogen has research and early development programs that are currently focused on discovering and developing novel medicines for serious infections caused by MDR gram-negative bacterial pathogens, including antibacterial monoclonal antibodies.
AKAO: 3.86 (-0.27)
Achaogen reports 1Q loss
Automated Insights - Thu May 05, 6:01PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Achaogen Inc. (AKAO) on Thursday reported a loss of $12.2 million in its first quarter.
AKAO: 3.86 (-0.27)
Achaogen Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017 --
AKAO: 3.86 (-0.27)
Achaogen Awarded $2.4 Million Contract Option by NIAID to Support Development of LpxC Inhibitors for the Treatment of Serious Bacterial Infections
GlobeNewswire - Thu Apr 21, 3:01PM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded an additional $2.4 million under an existing contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.
AKAO: 3.86 (-0.27)
Can The Uptrend Continue for Achaogen (AKAO)?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:59AM CDT
Investors certainly have to be happy with Achaogen, Inc. (AKAO) and its short term performance
AKAO: 3.86 (-0.27)
Achaogen to Present at the 15th Annual Needham Health Care Conference
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 15 Annual Needham Health Care Conference taking place April 12 to 13, 2016 at the Westin NY Grand Central Hotel, New York, NY. Achaogen's management will present at 10:40 a.m. Eastern Time on Wednesday, April 13, 2016.
AKAO: 3.86 (-0.27)
Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the acceleration of the expected timeline for reporting results from the Company's ongoing Phase 3 EPIC registration clinical trial of plazomicin, the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 19.65 (-0.87), BXE: 1.17 (-0.05), BKCC: 7.78 (-0.06), AKAO: 3.86 (-0.27), ATRC: 15.47 (-0.44)
Can Cintas (CTAS) Maintain the Earnings Momentum in Q3?
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 8:20AM CDT
Cintas Corporation (CTAS) is scheduled to report third-quarter fiscal 2016 results after the closing bell on Mar 22.
CTAS: 94.52 (-1.02), AKAO: 3.86 (-0.27), BRKR: 24.80 (-0.81), ATR: 78.20 (+0.41)
Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Mar 15, 6:00AM CDT
-- Commenced Pivotal Phase 3 EPIC Study of Plazomicin in Complicated Urinary Tract Infections; Continue to Expect Top-Line Data and NDA Submission in the Second Half of 2017 --
AKAO: 3.86 (-0.27)
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2015 Financial Results on March 15, 2016
GlobeNewswire - Tue Mar 08, 7:00AM CST
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter and year 2015 financial results on Tuesday, March 15, 2016 before the opening of the U.S. financial markets. Following the results announcement, management will host a conference call and live webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
AKAO: 3.86 (-0.27)
Acinetobacter Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/923dq5/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acinetobacter Infections Overview - Therapeutics Development - Pipeline Products for Acinetobacter Infections - Overview - Pipeline Products for Acinetobacter Infections - Comparative Analysis - Acinetobacter Infections - Therapeutics under Development by Companies - Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes - Acinetobacter Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acinetobacter Infections - Products under Development by Companies - Acinetobacter Infections - Products under Investigation by Universities/Institutes - Acinetobacter Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca Plc - AvidBiotics Corp. - Emergent BioSolutions Inc. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FAB Pharma - FOB Synthesis, Inc. - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/92...netobacter
TTPH: 3.94 (-0.17), SYN: 1.81 (unch), EBS: 42.30 (-1.19), SRPT: 19.95 (-1.04), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27), APHB: 1.68 (-0.07)
Resistant Pseudomonas Aeruginosa Infections Therapeutic Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/653sd8/resistant) has announced the addition of the "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Resistant Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis - Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies - Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Phico Therapeutics Limited - Phylogica Limited - Shionogi & Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/653sd8/resistant
AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27)
Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting
GlobeNewswire - Thu Jun 09, 7:30AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced six upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2016 Annual Meeting. The Company and its collaborators will make two oral presentations and present four posters at the event, which will be held at the Boston Convention and Exhibition Center (BCEC) from June 16 to 20, 2016. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen (AKAO) Shows Strength: Stock Moves 13% Higher
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:15AM CDT
Achaogen, Inc. (AKAO) shares rose around 13% in the last trading session.
AKAO: 3.86 (-0.27), JNP: 6.91 (-0.06)
Achaogen Adds Tobin Schilke as Chief Financial Officer
GlobeNewswire - Fri Jun 03, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Mr. Tobin Schilke as Chief Financial Officer, effective July 5, 2016. Mr. Schilke will serve as Achaogen's principal financial and accounting officer and will report to Kenneth Hillan, Chief Executive Officer.
AKAO: 3.86 (-0.27)
Achaogen Raises $25 Million in Private Placement
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has entered into an agreement to sell shares of its common stock and warrants to purchase shares of its common stock for aggregate gross proceeds of approximately $25 million in a private placement. New Enterprise Associates (NEA), one of the largest biotechnology investors worldwide, led the placement and was joined by EcoR1 Capital, LLC and additional new investors. Achaogen expects to use proceeds of the financing to advance its research and development programs and for general corporate purposes. The Company's lead product candidate, plazomicin, is being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
SLRC: 18.78 (-0.07), AKAO: 3.86 (-0.27)
Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded $20 million for an additional option, Option 3, on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of plazomicin. Plazomicin is the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
GlobeNewswire - Thu Jun 02, 6:55AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has achieved over 50 percent patient enrollment in its ongoing Phase 3 EPIC registration clinical trial of plazomicin. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
Achaogen and Crystal Bioscience Enter into Collaboration and License Agreement to Identify and Develop Antibodies for Multiple Targets
GlobeNewswire - Tue May 10, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, and Crystal Bioscience, Inc. (Crystal Bioscience), an antibody discovery company with a patented chicken-based discovery platform "powered by evolution," today announced that they have entered into a multiyear Collaboration and License Agreement to discover unique monoclonal antibodies against multiple targets. Achaogen has research and early development programs that are currently focused on discovering and developing novel medicines for serious infections caused by MDR gram-negative bacterial pathogens, including antibacterial monoclonal antibodies.
AKAO: 3.86 (-0.27)
Achaogen reports 1Q loss
Automated Insights - Thu May 05, 6:01PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Achaogen Inc. (AKAO) on Thursday reported a loss of $12.2 million in its first quarter.
AKAO: 3.86 (-0.27)
Achaogen Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017 --
AKAO: 3.86 (-0.27)
Achaogen Awarded $2.4 Million Contract Option by NIAID to Support Development of LpxC Inhibitors for the Treatment of Serious Bacterial Infections
GlobeNewswire - Thu Apr 21, 3:01PM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded an additional $2.4 million under an existing contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.
AKAO: 3.86 (-0.27)
Can The Uptrend Continue for Achaogen (AKAO)?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:59AM CDT
Investors certainly have to be happy with Achaogen, Inc. (AKAO) and its short term performance
AKAO: 3.86 (-0.27)
Achaogen to Present at the 15th Annual Needham Health Care Conference
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 15 Annual Needham Health Care Conference taking place April 12 to 13, 2016 at the Westin NY Grand Central Hotel, New York, NY. Achaogen's management will present at 10:40 a.m. Eastern Time on Wednesday, April 13, 2016.
AKAO: 3.86 (-0.27)
Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the acceleration of the expected timeline for reporting results from the Company's ongoing Phase 3 EPIC registration clinical trial of plazomicin, the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
AKAO: 3.86 (-0.27)
New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 19.65 (-0.87), BXE: 1.17 (-0.05), BKCC: 7.78 (-0.06), AKAO: 3.86 (-0.27), ATRC: 15.47 (-0.44)
Can Cintas (CTAS) Maintain the Earnings Momentum in Q3?
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 8:20AM CDT
Cintas Corporation (CTAS) is scheduled to report third-quarter fiscal 2016 results after the closing bell on Mar 22.
CTAS: 94.52 (-1.02), AKAO: 3.86 (-0.27), BRKR: 24.80 (-0.81), ATR: 78.20 (+0.41)
Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Mar 15, 6:00AM CDT
-- Commenced Pivotal Phase 3 EPIC Study of Plazomicin in Complicated Urinary Tract Infections; Continue to Expect Top-Line Data and NDA Submission in the Second Half of 2017 --
AKAO: 3.86 (-0.27)
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2015 Financial Results on March 15, 2016
GlobeNewswire - Tue Mar 08, 7:00AM CST
Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter and year 2015 financial results on Tuesday, March 15, 2016 before the opening of the U.S. financial markets. Following the results announcement, management will host a conference call and live webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
AKAO: 3.86 (-0.27)
Acinetobacter Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/923dq5/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acinetobacter Infections Overview - Therapeutics Development - Pipeline Products for Acinetobacter Infections - Overview - Pipeline Products for Acinetobacter Infections - Comparative Analysis - Acinetobacter Infections - Therapeutics under Development by Companies - Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes - Acinetobacter Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acinetobacter Infections - Products under Development by Companies - Acinetobacter Infections - Products under Investigation by Universities/Institutes - Acinetobacter Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca Plc - AvidBiotics Corp. - Emergent BioSolutions Inc. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FAB Pharma - FOB Synthesis, Inc. - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/92...netobacter
TTPH: 3.94 (-0.17), SYN: 1.81 (unch), EBS: 42.30 (-1.19), SRPT: 19.95 (-1.04), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27), APHB: 1.68 (-0.07)
Resistant Pseudomonas Aeruginosa Infections Therapeutic Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/653sd8/resistant) has announced the addition of the "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Resistant Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis - Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies - Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Phico Therapeutics Limited - Phylogica Limited - Shionogi & Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/653sd8/resistant
AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27)
